Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC.

J Natl Cancer Inst. 2006 Sep 6;98(17):1193-203.

PMID:
16954472
2.

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC.

J Clin Oncol. 2012 Oct 1;30(28):3525-32. Epub 2012 Aug 27.

3.
4.

Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.

Tsai HY, Hsi BL, Hung IJ, Yang CP, Lin JN, Chen JC, Tsai SF, Huang SF.

Hum Pathol. 2004 Nov;35(11):1397-403.

PMID:
15668898
5.

Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.

Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE.

Clin Cancer Res. 2006 Oct 1;12(19):5693-7.

6.

MYCN gene amplification in patients with neuroblastic tumors.

Estiar MA, Fazilaty H, Aslanabadi S, Seifi M, Varghaei P, Rezamand A.

Cell Mol Biol (Noisy-le-grand). 2014 Sep 16;60(3):23-8.

PMID:
25231001
7.

Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A.

Oncogene. 2005 Nov 24;24(53):7902-12.

PMID:
16103881
8.

Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.

Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A.

Oncogene. 2008 Jan 17;27(4):441-9. Epub 2007 Jul 16.

PMID:
17637744
9.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

10.

Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

PMID:
7674334
11.

Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M.

Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.

PMID:
21288077
12.

Prognostic value of MYCN and ID2 overexpression in neuroblastoma.

Alaminos M, Gerald WL, Cheung NK.

Pediatr Blood Cancer. 2005 Dec;45(7):909-15.

PMID:
16047351
13.

Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.

de Souza DR, Sanabani SS, de Souza AC, Filho Odone V, Epelman S, Bendit I.

Pediatr Blood Cancer. 2011 May;56(5):749-56. doi: 10.1002/pbc.22823. Epub 2010 Dec 9.

PMID:
21154590
14.

Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.

Combaret V, Audoynaud C, Iacono I, Favrot MC, Schell M, Bergeron C, Puisieux A.

Cancer Res. 2002 Jul 1;62(13):3646-8.

15.

Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.

Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M.

J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19.

PMID:
15316056
16.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

17.

Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.

Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M.

Clin Cancer Res. 2008 Oct 15;14(20):6590-601. doi: 10.1158/1078-0432.CCR-07-4377.

18.

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.

Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S.

J Pediatr Surg. 2004 Jan;39(1):63-8.

PMID:
14694373
19.

WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

Masserot C, Liu Q, Nguyen E, Gattolliat CH, Valteau-Couanet D, Bénard J, Huber C, Ségal-Bendirdjian E.

Mol Oncol. 2016 Feb;10(2):240-52. doi: 10.1016/j.molonc.2015.09.010. Epub 2015 Oct 21.

20.

[Study on MYCN gene amplification and CD44 expression in neuroblastoma].

Hu HL, He LJ.

Zhonghua Bing Li Xue Za Zhi. 2004 Aug;33(4):332-6. Chinese.

PMID:
15363318

Supplemental Content

Support Center